What Is Cryotherapy for Prostate Cancer?

Prostate cryotherapy is an ablative treatment. Rather than removing the prostate surgically, the urologist places thin cryoprobes into the gland and uses very cold gases to freeze selected prostate tissue.

The freezing process creates an ice ball inside the treatment zone. Repeated freezing and thawing damages cell membranes, blood vessels and other structures needed for tissue survival, leading to destruction of the treated tissue.

You may see several names used for essentially the same treatment concept:

• prostate cryotherapy;
• cryoablation;
• cryosurgery;
• focal cryotherapy; and
• whole-gland cryotherapy.

The important question is not simply whether cryotherapy can freeze prostate tissue. It can. The more important clinical question is whether cryotherapy offers the right balance of cancer control, side effects and future treatment options for a particular patient.

How Is Prostate Cryotherapy Performed?

Cryotherapy is usually performed under anesthesia. The exact technique varies by treatment system and center.

The ultrasound probe is placed in the rectum to image the prostate. The cryoprobes themselves are inserted through the perineum—the skin between the scrotum and anus—and advanced into selected areas of the prostate under image guidance.

Very cold gas is passed through the cryoprobes to freeze the target tissue. The prostate is then allowed to thaw, and treatment commonly includes more than one freeze-thaw cycle.

How Are Nearby Structures Protected?

The prostate is close to the urethra, urinary sphincter, rectum and nerves involved in erections. Modern systems therefore use several safety measures.

• Transrectal ultrasound is used to monitor the developing ice ball.
• Temperature probes may be positioned near important structures.
• Warm fluid can be circulated through a urethral catheter to reduce the risk of freezing the urethra.
• The number and position of cryoprobes are planned according to the treatment field.

These techniques reduce risk but do not eliminate complications.

Focal Cryotherapy vs Whole-Gland Cryotherapy

Cryotherapy does not always mean freezing the entire prostate.

Focal treatment depends on accurate cancer mapping. Multiparametric magnetic resonance imaging (MRI) and targeted plus systematic biopsy are important because prostate cancer can be multifocal.

Who Might Be Considered for Cryotherapy?

There is no single PSA level or Gleason score that automatically makes someone suitable for cryotherapy.

Assessment may include:

• prostate-specific antigen (PSA) level and PSA trend;
• Grade Group / Gleason score;
• clinical stage;
• multiparametric MRI;
• targeted and systematic biopsy findings;
• number and distribution of cancer foci;
• prostate size and anatomy;
• baseline urinary function;
• erectile function;
• previous prostate treatment;
• life expectancy and other medical conditions; and
• the patient’s priorities regarding cancer control and quality of life.

Cryotherapy may be discussed in selected men with localized disease who are considering an ablative approach, and in selected men with a local recurrence after radiotherapy.

Is Cryotherapy a Standard First Treatment for Localized Prostate Cancer?

No—not for most men.

The role of primary focal or whole-gland ablation remains less established than radical prostatectomy, modern radiotherapy and active surveillance.

What Does the EAU Say?

Current European Association of Urology guidance states that focal therapy using HIFU or cryotherapy should be performed within the context of a prospective registry. The guideline emphasizes that robust long-term comparative evidence is still needed before focal therapy can be recommended without restriction for routine practice.

What Does the AUA/ASTRO Guideline Say?

The American guidance is somewhat more permissive but still cautious. It states that men with intermediate-risk prostate cancer considering focal or whole-gland ablation should be told that high-quality comparative data versus surgery, radiotherapy and active surveillance are lacking.

The American Urological Association/American Society for Radiation Oncology (AUA/ASTRO) guideline states that ablation may be considered in selected, appropriately informed patients, with clinical-trial enrollment prioritized. Low-risk prostate cancer is generally better managed with active surveillance, while high-risk disease should not be treated with focal or whole-gland ablation outside a clinical trial.

What About Low-, Intermediate- and High-Risk Prostate Cancer?

Low-Risk Disease

Many men with genuinely low-risk localized prostate cancer do not need immediate treatment. Active surveillance can avoid urinary and sexual side effects while retaining the option to treat later if the cancer shows evidence of progression.

Intermediate-Risk Disease

This is the risk group in which focal ablation is most often discussed. Even here, cancer location, MRI visibility, biopsy distribution, Grade Group and patient preferences matter greatly. The patient should understand that comparative long-term evidence is less mature than for surgery and radiotherapy.

High-Risk Disease

Focal or whole-gland cryotherapy is not established routine treatment for high-risk localized prostate cancer. AUA/ASTRO advises against whole-gland or focal ablation for high-risk disease outside a clinical trial.

What Is Salvage Cryotherapy After Radiation?

Salvage cryotherapy is cryoablation used after prostate cancer has returned locally following previous radiotherapy.

This situation is very different from treating an untreated prostate. Radiation changes tissue blood supply, elasticity and healing, which can increase the risk of complications from later local treatment.

Who Might Be Considered?

A rising PSA after radiotherapy does not by itself prove that cancer is still confined to the prostate. Before local salvage treatment, clinicians generally need to determine whether recurrence is truly local and whether there is evidence of metastatic disease.

The AUA/ASTRO/SUO guideline specifically recommends prostate biopsy before local salvage therapy in candidates with biochemical recurrence after radiotherapy. Imaging, including modern positron emission tomography/computed tomography (PET/CT) in appropriate cases, can help identify metastatic disease, but local salvage treatment should not be based on a positive scan alone without pathological confirmation.

Guidelines Differ Somewhat on Salvage Cryotherapy

The EAU takes a restrictive approach and recommends salvage cryoablation for highly selected patients with biopsy-proven local recurrence within clinical trials or well-designed prospective cohorts at experienced centers.

In the United States, the AUA/ASTRO/SUO salvage guideline states that men with biopsy-documented recurrence after primary radiotherapy who are candidates for local salvage therapy should be offered a shared-decision choice that can include:

• salvage radical prostatectomy;
• cryoablation;
• HIFU; or
• reirradiation.

This recommendation is based on limited-quality evidence, and counseling should emphasize the higher risk of urinary, sexual and bowel complications after treatment of previously irradiated tissues.

What Is the Success Rate of Cryotherapy for Prostate Cancer?

There is no single reliable “success rate” for prostate cryotherapy.

Outcomes vary according to whether cryotherapy is primary or salvage treatment, focal or whole-gland, the patient’s Grade Group and PSA, cancer distribution, previous radiotherapy, definition of biochemical failure and length of follow-up.

Salvage Cryotherapy After Radiotherapy

The EAU cites a systematic review of 32 salvage cryoablation studies including 5,513 patients. Most patients received whole-gland salvage cryotherapy.

In the adjusted pooled analysis, biochemical-recurrence-free survival was approximately:

• 67% at 2 years; and
• 50% at 5 years.

The guideline stresses that the certainty of this evidence is low.

Another systematic review and meta-analysis reported recurrence-free survival of approximately 68% at 2 years, 60% at 3 years and 47% at 5 years.

These figures should not be interpreted as universal cure rates. They describe outcomes across selected study populations using varying definitions and treatment techniques.

Primary Focal Cryotherapy

Modern focal-therapy series report encouraging medium-term cancer control in selected men, but focal cryotherapy does not yet have the same depth of long-term randomized comparative evidence as radical prostatectomy or modern radiotherapy.

Retreatment is not uncommon after focal therapy. Some men ultimately require repeat ablation, surgery, radiotherapy or another treatment. Rates vary substantially between studies and protocols, so a single retreatment percentage should not be presented as though it applies to every patient.

Recovery After Prostate Cryotherapy: What Should You Expect?

What Are the Side Effects and Risks of Cryotherapy?

Risk depends strongly on how much prostate tissue is treated and whether the prostate has previously received radiotherapy.

For a broader comparison of treatment-related problems, see Prostate Cancer Treatment Side Effects: Surgery, Radiation, Hormone Therapy and Chemotherapy.

Can Cryotherapy Cause Erectile Dysfunction?

Yes.

Erectile dysfunction is one of the most important long-term risks of prostate cryotherapy. The nerves responsible for erections run close to the prostate and can be affected by freezing.

Whole-gland cryotherapy generally carries a greater sexual-function risk than carefully selected focal treatment because a larger volume of prostate and adjacent tissue is exposed to the treatment field.

Focal cryotherapy may reduce the risk by preserving more tissue and potentially sparing one or both neurovascular bundles, but preservation of erections is never guaranteed.

Risk also depends on erectile function before treatment, age, cardiovascular health, tumor location and the amount of tissue that must be treated.

What Happens to PSA After Cryotherapy?

PSA should fall after prostate cryotherapy because viable prostate tissue has been destroyed, but PSA interpretation is not the same as after radical prostatectomy.

After radical prostatectomy, nearly all prostate tissue is removed and PSA is expected to become very low or undetectable.

After focal cryotherapy, untreated prostate tissue remains and continues to produce PSA. A measurable PSA therefore does not automatically mean that cryotherapy failed.

PSA trends need to be interpreted together with the amount of tissue treated, MRI findings, clinical assessment and—in many focal-treatment protocols—repeat biopsy.

Do You Still Need MRI or Biopsy After Focal Cryotherapy?

Yes. Long-term surveillance remains essential.

Focal treatment intentionally leaves some prostate tissue untreated. Follow-up may include:

• serial PSA testing;
• clinical review;
• multiparametric MRI;
• targeted biopsy; and
• systematic biopsy according to the treatment protocol and clinical findings.

The purpose is to identify persistent cancer in the treated area, recurrence within that area, or clinically significant cancer in another part of the prostate.

How Does Cryotherapy Compare With Other Prostate Cancer Treatments?

Cryotherapy vs Radical Prostatectomy

Radical prostatectomy removes the prostate and has mature long-term oncological outcome data. Cryotherapy avoids removal of the gland and usually involves less blood loss and a shorter initial recovery.

The trade-off is that primary focal cryotherapy has less mature long-term comparative evidence and leaves untreated prostate tissue requiring ongoing surveillance.

Cryotherapy vs Radiotherapy

Modern radiotherapy has a well-established role across multiple localized and locally advanced prostate-cancer risk groups. Cryotherapy does not expose the patient to ionizing radiation, but it deliberately destroys tissue through freezing and can still cause significant urinary and sexual complications.

Is Cryotherapy Better Than HIFU?

There is no universal answer.

Cryotherapy destroys tissue through freezing. HIFU destroys tissue through focused heat generated by high-intensity ultrasound. Both can be used as focal ablative strategies in selected patients and both require careful cancer mapping and continued surveillance.

Choice depends on cancer location, prostate anatomy, previous treatment, local expertise and the evidence available for the specific clinical situation.

Read the full comparison background in HIFU for Prostate Cancer: Procedure, Benefits, Risks and Who May Be Eligible.

Cryotherapy vs Active Surveillance

For many men with low-risk prostate cancer, active surveillance avoids immediate treatment altogether. That is a meaningful advantage when the cancer is unlikely to cause harm in the near term.

Cryotherapy should therefore not be chosen merely because it seems less invasive than surgery. The first question is whether the cancer needs immediate treatment at all.

Can Diet, Vitamins or Supplements Improve Cryotherapy Results?

Diet and antioxidant supplements are sometimes promoted around prostate-cancer treatment, but they have not been shown to make cryotherapy more effective or to reliably prevent recurrence after ablation.

A balanced dietary pattern emphasizing vegetables, whole fruit, legumes, whole grains, nuts, seeds and appropriate protein sources can support general health, but it should not be presented as a substitute for cancer treatment or surveillance.

High-dose vitamin E, selenium or other “prostate cancer” supplements should not be started simply because a patient is having cryotherapy. Supplements can cause harm or interact with other treatment, and some have failed to show benefit in major prostate-cancer prevention trials.

Questions to Ask Before Choosing Cryotherapy

1. What is my exact Grade Group and Gleason score?
2. Is my cancer confined to the prostate?
3. How many cancer areas were found on MRI and biopsy?
4. Am I being offered focal or whole-gland cryotherapy?
5. Would active surveillance be reasonable for my cancer?
6. Why is cryotherapy preferable to surgery or radiotherapy in my specific situation?
7. How many prostate cryotherapy procedures has this center performed?
8. What are this center’s rates of retreatment?
9. What are its rates of erectile dysfunction, urinary retention and incontinence?
10. How long will I need a catheter?
11. How will PSA be interpreted after treatment?
12. When will I have another MRI?
13. Will I need a repeat biopsy?
14. If cancer remains or returns, what treatments will still be available?
15. If this is salvage treatment after radiotherapy, what are my alternatives?

Frequently Asked Questions